Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer.
来源：PubMed发布日期：2026-07-31作者：Jackisch C, Im SA, Mattar A, Colomer R, Stroyakovskiy D0 次点击